RxDoctor Payments Data

Atul Madan, MD

Interventional Cardiology · Kissimmee, FLNPI 1528153236

Payments from drug & device makers

$3,133in general payments, 2019–2025

Across 121 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$604
  • Medtronic$384
  • Pfizer$264
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$233
  • Abbott$220
  • Novartis$194
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,02096%
  • Education$1144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,133 in reported general payments places this provider in the 20th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$216,161
Medicare patients
1,084
Services billed
2,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$124,437
FarxigaDapagliflozin Propanediol23$25,202
JardianceEmpagliflozin18$21,682
BrilintaTicagrelor16$18,488
Ranolazine ErRanolazine29$3,048
Metoprolol Succinate160$2,392
Isosorbide Mononitrate ErIsosorbide Mononitrate112$1,712
Carvedilol162$1,556
Atorvastatin Calcium137$1,211
Losartan Potassium132$1,114
Rosuvastatin Calcium65$980
Amlodipine Besylate103$903
Ezetimibe42$843
Torsemide41$823
FenofibrateFenofibrate Nanocrystallized20$624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$264$124,437117 claims
AstraZenecaFarxiga, Brilinta$14$43,69139 claims
Boehringer IngelheimJardiance$24$21,68218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →